The global proteasome inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). Proteasomes are protein complexes that degrade unneeded or damaged proteins by proteolysis. Additionally, enzymes that support such reactions are known as proteases. Furthermore, the proteasome is a cylindrical complex that contains a core of four stacked rings which forms a central pore. The major factor driving the growth of the market is the rising prevalence of lymphoma across the globe.
Get Free Sample link @ https://www.omrglobal.com/request-sample/proteasome-inhibitors-market
According to the Leukemia & Lymphoma Society, one person is diagnosed with lymphoma approximately every 3 minutes in the US. Additionally, in 2021, an estimated combined total of 186,400 people are anticipated to be diagnosed with leukemia, lymphoma or myeloma in the US. Furthermore, in 2021, new cases of leukemia, lymphoma and myeloma are anticipated to account for 9.8% of the estimated 1,898,160 new cancer cases. Moreover, an estimated 1,519,907 people are living with or in remission from leukemia, lymphoma, myeloma in the US. Hence, the increasing prevalence of lymphoma is driving the demand for proteasome inhibitors as they mediate cell cycle arrest and apoptosis causing dysregulation of several proapoptotic proteins.
Some major players in the market include Johnson and Johnson Services, Inc., Amgen, Inc., and Celgene Corp., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in February 2021, Oncopeptides AB announced that it has received approval for melphalan flufenamide from the US FDA. It is used in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma.
Full report of Proteasome Inhibitors Market available @ https://www.omrglobal.com/industry-reports/proteasome-inhibitors-market
Market Coverage
- Segment Covered-
o By Drugs
o By Application
o By Distribution Channel
o By End-Users
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Johnson and Johnson Services, Inc., Amgen, Inc., and Celgene Corp., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Proteasome Inhibitors Market Report by Segment
By Drugs
- Bortezomib
- Carfilzomib
- Ixazomib
By Application
- Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
By Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/proteasome-inhibitors-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
